AR072750A1 - Anticuerpos modificadores de enfermedades cancerosas - Google Patents
Anticuerpos modificadores de enfermedades cancerosasInfo
- Publication number
- AR072750A1 AR072750A1 ARP090102679A ARP090102679A AR072750A1 AR 072750 A1 AR072750 A1 AR 072750A1 AR P090102679 A ARP090102679 A AR P090102679A AR P090102679 A ARP090102679 A AR P090102679A AR 072750 A1 AR072750 A1 AR 072750A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- cancer
- idac
- registration number
- cancerose
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un método para producir anticuerpos modificadores de enfermedades cancerosas empleando un nuevo paradigma de exploracion. Segregando anticuerpos anticancerosos empleando la citotoxicidad celular como criterio, el proceso hace posible la produccion de anticuerpos anticancerosos para fines terapéuticos y de diagnostico. Los anticuerpos pueden utilizarse para facilitar la clasificacion y diagnostico del cáncer y pueden utilizarse para tratar tumores primarios y metástasis de tumores. Los anticuerpos anticancerosos pueden conjugarse con toxinas, enzimas, compuestos radiactivos y células hematogénicas. Reivindicacion 1: El anticuerpo monoclonal aislado producido por el hibridoma depositado en la IDAC con el numero de registro 040608-01 Reivindicacion 4: La línea celular de hibridoma aislada depositada en la IDAC con el numero de registro 040608-01.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8155308P | 2008-07-17 | 2008-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072750A1 true AR072750A1 (es) | 2010-09-15 |
Family
ID=41327715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102679A AR072750A1 (es) | 2008-07-17 | 2009-07-15 | Anticuerpos modificadores de enfermedades cancerosas |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100015045A1 (es) |
EP (1) | EP2313437A1 (es) |
JP (1) | JP2011528010A (es) |
AR (1) | AR072750A1 (es) |
CA (1) | CA2731129A1 (es) |
TW (1) | TW201006929A (es) |
WO (1) | WO2010007000A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10412962B2 (en) | 2015-11-25 | 2019-09-17 | North Carolina Agricultural And Technical State University | Antifungal compositions and methods of use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4171655A (en) * | 1978-07-13 | 1979-10-23 | Western Printing Machinery Co. | Stabilized center-distance adjuster for rotary die cutters |
US4828991A (en) * | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
AU613590B2 (en) * | 1986-11-19 | 1991-08-08 | Bristol-Myers Squibb Company | Hybridomas producing monoclonal antibodies to new mucin epitopes |
US4861581A (en) * | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
EP0539970B1 (en) * | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
IL105008A0 (en) * | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
ATE244888T1 (de) * | 1993-02-05 | 2003-07-15 | Epigen Inc | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
ES2150573T3 (es) * | 1994-06-24 | 2000-12-01 | Vladimir P Torchilin | Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales. |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6794494B1 (en) * | 2003-04-14 | 2004-09-21 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US6180357B1 (en) * | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
US20060140963A1 (en) * | 2003-04-14 | 2006-06-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US20050027106A1 (en) * | 2003-07-28 | 2005-02-03 | Young David S. F. | Cancerous disease modifying antibodies |
US7411046B2 (en) * | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
US7452979B2 (en) * | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7494648B2 (en) * | 2005-08-02 | 2009-02-24 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
-
2009
- 2009-07-10 EP EP09780426A patent/EP2313437A1/en not_active Withdrawn
- 2009-07-10 WO PCT/EP2009/058817 patent/WO2010007000A1/en active Application Filing
- 2009-07-10 JP JP2011517880A patent/JP2011528010A/ja not_active Withdrawn
- 2009-07-10 CA CA2731129A patent/CA2731129A1/en not_active Abandoned
- 2009-07-15 AR ARP090102679A patent/AR072750A1/es unknown
- 2009-07-15 TW TW098123952A patent/TW201006929A/zh unknown
- 2009-07-16 US US12/504,473 patent/US20100015045A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100015045A1 (en) | 2010-01-21 |
EP2313437A1 (en) | 2011-04-27 |
TW201006929A (en) | 2010-02-16 |
CA2731129A1 (en) | 2010-01-21 |
WO2010007000A1 (en) | 2010-01-21 |
JP2011528010A (ja) | 2011-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1718737T3 (da) | Cancerøs sygdomsmodificerende antistoffer | |
WO2007095749A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of trop-2 | |
MX2009007619A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
BR112021026293A2 (pt) | Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula | |
CY1106455T1 (el) | Τροποποιητικα αντισωματα καρκινικης νοσου | |
HRP20210410T1 (hr) | Konjugirana antitijela prema ly75 za liječenje raka | |
ECSP12012138A (es) | Anticuerpo monoclonico anti-cd44 que liga el carcinoma escamocelular de cabeza y cuello | |
MX2009007618A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
MX2009007617A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
MX2009001015A (es) | Anticuerpos modificadores de enfermedad cancerosa. | |
WO2004065422A3 (en) | Cancerous disease modifying antibodies | |
AR072750A1 (es) | Anticuerpos modificadores de enfermedades cancerosas | |
WO2005012361A3 (en) | Antibodies raised against colon carcinomas | |
AR070279A1 (es) | Anticuerpos modificadores de enfermedades cancerosas (cdma) | |
MX2009009919A (es) | Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma. | |
MX2009011667A (es) | Anticuerpos de modificacion de enfermedad cancerosa. | |
AR070280A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab) | |
AR071847A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas | |
ATE483028T1 (de) | Antikörper, die krebserkrankungen modifizieren | |
MX2009001292A (es) | Anticuerpos modificadores de enfermedad cancerosa. | |
AR070278A1 (es) | Aislamiento y produccion de anticuerpos modificadores de enfermedades cancerosas (cdmab) y uso de los mismos | |
AR071308A1 (es) | Anticuerpos monoclonales (producidos por el hibridoma idac 200208-03), que modifican enfermedades cancerosas | |
WO2008058380A8 (en) | Cancerous disease modifying antibodies | |
NO20091459L (no) | Cancerose sykdomsmodifiserende antistoffer | |
BRPI0718609A8 (pt) | Anticorpos modificadores de doença cancerosa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |